Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Imvotamab in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Failed Prior Therapies

NCT06087406 is registered in ClinicalTrials.gov with IGM Biosciences, Inc. as lead sponsor.

NCT NCT06087406
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06087406 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Imvotamab in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Failed Prior Therapies
Lead sponsor
IGM Biosciences, Inc.
Phase
Phase 1
Overall status
Terminated
Start date
March 15, 2023
Completion date
February 10, 2025
Enrollment
33 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

arthritis, arthritis, rheumatoid, rheumatoid arthritis